Strategy+ Advises Pfizer (NYSE: PFE) on Joint Venture with GlaxoSmithKline PLC (NYSE: GSK)

By

Strategy+ originated and advised Pfizer (NYSE: PFE) on the $18 Billion joint venture with GlaxoSmithKline PLC (NYSE: GSK).

Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on a joint venture with GlaxoSmithKline plc (NYSE:GSK) to create a premier global consumer healthcare company with robust iconic brands. Under the transaction, Pfizer contributed its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The agreement was announced December 18, 2018. The Joint Venture was valued at $16 Billion.

‍

Read the transaction press release

Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

strategyadd.com (the “Strategy Group LLC Website”) is a website operated by Strategy Group LLC, a privately held Florida limited liability company. Strategy Group LLC is not a registered broker-dealer. Strategy Group LLC provides strategic advisory and consulting services strictly in connection with mergers and acquisitions and capital raising. Strategy Group LLC does not act as a broker-dealer, does not engage in securities transactions, and does not receive transaction-based compensation. Strategy Group LLC’s services are limited to strategic advisory, and it does not perform or facilitate securities sales or trades.